ILDR2 Is a novel B7-like protein that negatively regulates T cell responses

Journal article

The B7-like protein family members play critical immunomodulatory roles and constitute attractive targets for the development of novel therapies for human diseases. We identified Ig-like domain–containing receptor (ILDR)2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer.

Authors: Hecht, I; Toporik, A; Podojil, JR; Vaknin, I; Cojocaru, G

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: American Association of Immunologists
• Journal: Journal of Immunology
• Volume: 200
• Issue: 6
• Pages: 2025-2037
• Publication date: 2018-03-15
• Acceptance date: 2018-01-03
• DOI: 10.4049/jimmunol.1700325
• EISSN: 1550-6606
• ISSN: 0022-1767
• Pmid: 29431694
• Language: English